In this paper the Working Group on Myocardial and Pericardial Disease proposes a revised
definition of dilated cardiomyopathy (DCM) in an attempt to bridge the gap between our …

Despite the advances that have been made in developing new therapeutics, cardiovascular
disease remains the leading cause of worldwide mortality. Therefore, understanding the …

Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …

Abstract Aims Lamin A/C (LMNA) mutations cause familial dilated cardiomyopathy (DCM)
with frequent conduction blocks and arrhythmias. We explored the prevalence, cardiac …

Remarkable progress has been made in understanding the genetic basis of dilated
cardiomyopathy (DCM). Rare variants in> 30 genes, some also involved in other …

Dilated cardiomyopathy (DCM) is an umbrella term entailing a wide variety of genetic and
non-genetic etiologies, leading to left ventricular systolic dysfunction and dilatation, not …

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disease.
HCM is a highly complex and heterogeneous disease regarding not only the number of …

Management strategies for ventricular arrhythmias are guided by the risk of sudden death
and severity of symptoms. Patients with a substantial risk of sudden death usually need an …

Most cardiomyopathies are familial diseases. Cascade family screening identifies
asymptomatic patients and family members with early traits of disease. The inheritance is …

The classes of recommendations and levels of evidence in these guidelines were
determined and described according to the “Guidelines for the treatment of acute and …